By Ransdell Pierson PHILADELPHIA, Nov 5 (Reuters) - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals. But the British drugmaker has not thrown in the tow
Read more* Vaccine primes immune system to attack viruses * Uses same science as Ebola shot being tested By Kate Kelland LONDON, Nov 5 (Reuters) - A new hepatitis C vaccine from GlaxoSmithKline based on the same technology as an experimental Ebola shot being fast-tracked through human tr
Read more** Hedge funds were burnt when Shire's deal with AbbVie fell through but 2 bulge bracket brokers now say pharma co a compelling investment as focus shifts to cheaper valuations and earnings growth that outstrips that of rivals. ** Hedge funds including Paulson & Co and Elliot lost hundred o
Read more* Frenchman Bohuon is Smith & Nephew's CEO since 2011 * Track record seen strong at U.S. and French firms * French nationals seen well-placed to handle unions, politics By Natalie Huet and Sophie Sassard PARIS/LONDON, Nov 4 (Reuters) - The French boss of British artificial
Read moreLONDON, Nov 3 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-maker
Read more